JP2018508532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508532A5 JP2018508532A5 JP2017546702A JP2017546702A JP2018508532A5 JP 2018508532 A5 JP2018508532 A5 JP 2018508532A5 JP 2017546702 A JP2017546702 A JP 2017546702A JP 2017546702 A JP2017546702 A JP 2017546702A JP 2018508532 A5 JP2018508532 A5 JP 2018508532A5
- Authority
- JP
- Japan
- Prior art keywords
- polr2a
- gene
- loss
- expression
- hemizygosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128480P | 2015-03-04 | 2015-03-04 | |
| US62/128,480 | 2015-03-04 | ||
| PCT/US2016/020687 WO2016141185A1 (en) | 2015-03-04 | 2016-03-03 | Methods of treating cancer harboring hemizygous loss of tp53 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180195A Division JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508532A JP2018508532A (ja) | 2018-03-29 |
| JP2018508532A5 true JP2018508532A5 (https=) | 2019-03-14 |
| JP6811718B2 JP6811718B2 (ja) | 2021-01-13 |
Family
ID=55586424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546702A Active JP6811718B2 (ja) | 2015-03-04 | 2016-03-03 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
| JP2020180195A Active JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180195A Active JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10563204B2 (https=) |
| EP (2) | EP3741855A1 (https=) |
| JP (2) | JP6811718B2 (https=) |
| KR (1) | KR102697493B1 (https=) |
| CN (1) | CN107847553A (https=) |
| AU (1) | AU2016226133B2 (https=) |
| BR (1) | BR112017018861A2 (https=) |
| CA (1) | CA2978632C (https=) |
| CY (1) | CY1123489T1 (https=) |
| DK (1) | DK3265565T3 (https=) |
| ES (1) | ES2831157T3 (https=) |
| HR (1) | HRP20201791T1 (https=) |
| HU (1) | HUE051776T2 (https=) |
| IL (2) | IL284264B (https=) |
| LT (1) | LT3265565T (https=) |
| MX (1) | MX379585B (https=) |
| PL (1) | PL3265565T3 (https=) |
| PT (1) | PT3265565T (https=) |
| RS (1) | RS61047B1 (https=) |
| RU (1) | RU2721953C2 (https=) |
| SG (2) | SG10201907746TA (https=) |
| SI (1) | SI3265565T1 (https=) |
| WO (1) | WO2016141185A1 (https=) |
| ZA (1) | ZA201706459B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201791T1 (hr) | 2015-03-04 | 2021-04-16 | Board Of Regents, The University Of Texas System | Postupci za liječenje raka sa hemizigotnim gubitkom gena tp53 |
| BR112018076306A2 (pt) | 2016-06-17 | 2019-03-26 | Magenta Therapeutics, Inc. | composições e métodos para a supressão de células cd117+ |
| MX395639B (es) | 2017-01-20 | 2025-03-25 | Heidelberg Pharma Res Gmbh | Composiciones y métodos para el agotamiento de células cd137+. |
| EP3873541A4 (en) * | 2018-10-30 | 2022-08-31 | Ohio State Innovation Foundation | PH-ACTIVATED NANOPARTICLES |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| CN114599374A (zh) | 2019-07-01 | 2022-06-07 | 卫材R&D管理有限公司 | 用于增强抗癌化合物e7766的治疗依从性的系统 |
| CN111569076B (zh) * | 2020-06-28 | 2022-05-17 | 中国农业科学院特产研究所 | Polr2a抑制剂在制备药物中的应用 |
| CN114875107B (zh) * | 2021-05-19 | 2025-05-27 | 中南大学 | Polr2a作为治疗肿瘤疗效的生物标志物 |
| CN113702648B (zh) * | 2021-09-13 | 2024-06-04 | 中南大学湘雅三医院 | Polr2a在作为预测抗肿瘤药物的抗肿瘤疗效的生物标志物上的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20110117212A1 (en) | 2008-07-24 | 2011-05-19 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
| JP2012523383A (ja) * | 2009-04-08 | 2012-10-04 | ファウルシュティヒ，ハインツ | がんの治療のためのアマトキシンと複合体形成した標的結合部分 |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| EP2774624A1 (en) * | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| EP3215519A1 (en) * | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| HRP20201791T1 (hr) | 2015-03-04 | 2021-04-16 | Board Of Regents, The University Of Texas System | Postupci za liječenje raka sa hemizigotnim gubitkom gena tp53 |
-
2016
- 2016-03-03 HR HRP20201791TT patent/HRP20201791T1/hr unknown
- 2016-03-03 LT LTEP16710890.1T patent/LT3265565T/lt unknown
- 2016-03-03 SG SG10201907746TA patent/SG10201907746TA/en unknown
- 2016-03-03 CN CN201680026012.9A patent/CN107847553A/zh active Pending
- 2016-03-03 EP EP20181578.4A patent/EP3741855A1/en active Pending
- 2016-03-03 SG SG11201707097RA patent/SG11201707097RA/en unknown
- 2016-03-03 DK DK16710890.1T patent/DK3265565T3/da active
- 2016-03-03 WO PCT/US2016/020687 patent/WO2016141185A1/en not_active Ceased
- 2016-03-03 EP EP16710890.1A patent/EP3265565B1/en active Active
- 2016-03-03 KR KR1020177028574A patent/KR102697493B1/ko active Active
- 2016-03-03 PL PL16710890T patent/PL3265565T3/pl unknown
- 2016-03-03 JP JP2017546702A patent/JP6811718B2/ja active Active
- 2016-03-03 ES ES16710890T patent/ES2831157T3/es active Active
- 2016-03-03 SI SI201630971T patent/SI3265565T1/sl unknown
- 2016-03-03 IL IL284264A patent/IL284264B/en unknown
- 2016-03-03 CA CA2978632A patent/CA2978632C/en active Active
- 2016-03-03 MX MX2017011298A patent/MX379585B/es unknown
- 2016-03-03 BR BR112017018861-9A patent/BR112017018861A2/pt not_active Application Discontinuation
- 2016-03-03 AU AU2016226133A patent/AU2016226133B2/en active Active
- 2016-03-03 PT PT167108901T patent/PT3265565T/pt unknown
- 2016-03-03 RS RS20201349A patent/RS61047B1/sr unknown
- 2016-03-03 HU HUE16710890A patent/HUE051776T2/hu unknown
- 2016-03-03 RU RU2017134347A patent/RU2721953C2/ru active
- 2016-03-03 US US15/555,411 patent/US10563204B2/en active Active
-
2017
- 2017-09-03 IL IL254271A patent/IL254271B/en unknown
- 2017-09-26 ZA ZA2017/06459A patent/ZA201706459B/en unknown
-
2019
- 2019-11-01 US US16/671,376 patent/US11479774B2/en active Active
-
2020
- 2020-10-28 JP JP2020180195A patent/JP7090933B2/ja active Active
- 2020-11-10 CY CY20201101053T patent/CY1123489T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508532A5 (https=) | ||
| Klemke et al. | Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer | |
| Banin Hirata et al. | Molecular markers for breast cancer: prediction on tumor behavior | |
| Hwang | Overcoming docetaxel resistance in prostate cancer: a perspective review | |
| Peeters et al. | Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer | |
| Farren et al. | Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy | |
| Shen et al. | TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization | |
| Pignot et al. | Systemic treatments for high-risk localized prostate cancer | |
| RU2017134347A (ru) | Способы лечения рака, имеющего гемизиготную потерю тр53 | |
| JP7032329B2 (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| Leblanc et al. | Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma | |
| Giuliano et al. | Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5 | |
| Wubetu et al. | High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Lundy et al. | TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma | |
| Zhuo et al. | TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer | |
| Liu et al. | Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis | |
| Scholfield et al. | Defining the genomic landscape of diffuse sclerosing papillary thyroid carcinoma: prognostic implications of RET fusions | |
| Klomp et al. | Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors | |
| ES2817331T3 (es) | Uso del cabazitaxel en el tratamiento del cáncer de próstata | |
| Gao et al. | Low SLC29A1 expression is associated with poor prognosis in patients with hepatocellular carcinoma | |
| KR20150132206A (ko) | 예측성 바이오마커에 대한 검정법 | |
| Gui et al. | Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial | |
| Li et al. | MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors | |
| Feghaly et al. | Bladder cancer treatments in the age of personalized medicine: A comprehensive review of potential radiosensitivity biomarkers |